They had 3 drugs, Nexavar, Kyprolis and Stivarga.
Nexavar - $1 billion a year in sales (partner w/Bayer);
Kyprolis - $400/m annual sales (no partner)
Stivarga - $20/million annual sales (out-licensed).
MRUYOG - Now you can explain why Amgen bought Onyx? Is it because Nexavar 50/50 share with Bayer that will soon have a generic? Maybe Amgen was looking at the 50/50 out-license deal with Stivarga that net's them about 60-75% or about $14-$15/million a year.
Oh wait, I know, I bet Amgen acquired Onyx due to Kyprolis with expected sales of $1.8 billion by 2018/2019, patent expiration in 2023 and oh yeah, no partner to share it with.
Wake up man, Kyprolis with Chip's baby @ Proteolix.
Do you think Amgen bought Onyx for a new address? Maybe their lawn was green due to having a better sprinkler system? Perhaps Amgen executives were simply bored.
Chippy was CEO of Proteolix which was sold to Onyx for $850/million, in which Onyx was later sold to Amgen for $9.7 billion, mostly due to the Proteolix drug, which was eventually approved by Onyx due to Chippy's research.
Who's better to choose from? You? Think not.
Hate to brag but he took a 16% drop on PTBI too. Guess he can't say he's green on that holding, fresh 52/wk low today. Due to some blog calling it a micro stock scan, $2 seems viable late this week into next week.
Gulp! Like Dean said.....TIMBERRRRRRRRRRRRRRRRR
Hit the 52/wk low even faster than I thought from some online blog calling the company a pump and dump into close today.
Not looking good for tomorrow Sal.
Win some, lose most right?
Sentiment: Strong Sell
Gene Therapy my friend.
Tons of frontrunners leading the pack - BLUE/KITE/ONCE/JUNO/QURE
Took a 15% bludgeoning, ohhh, soooo called that 52/wk low.
Heading to $2.00-$2.25 within days.
Sentiment: Strong Sell
What makes this stock more attractive is that it's going to be setting new 52/week lows in the next 2-3 weeks. Delisting is just around the corner by early 2016.
It simply means nobody died due to taking the drug, hence trial would've been halted.
I'm holding/long into the results, however if you recall, Affymax (AFFY)....Omontsys was safe too, nobody died, trials proceeded, then got approved to complete with Amgen's drug.
Then....somebody died, then another person died, etc.
Now you can guess how this story ended.
I'm pleased that nobody died thus far regarding CLDN's trial. Let's just hope the trial works now.
With short interest drying up at a current run rate of 1 to 1.5m shares every two weeks, this is precisely what is occurring.
We're down from 30m shorts to 24/m shares short. The stock is up nearly 300% off the 52/wk low. Most of the new shorts (prob 98%) are drowning and in the red.
The tide is turning here. GERN is only heading one direction, onward and upward.
Disregard anything BlackMarango says, he's uber short and will take his short to either bankruptcy or the grave (buyout).
Look at the 5.2m shares short in PCYC that got nuked the day Abbvie was announced in a 3/way bidding way. 5.2m shares were short simply got destroyed and probably some folks were short from $10, $20, $50 or $100 range. We all know how their fate turned out. Took their short positions to the grave. BM is just noise on this board and his opinion, while worth a good read or laugh, should be taken with a grain of salt.
Sentiment: Strong Buy
With a nice PR splash of good news, you'll find another 25% of the shorts vaporized and the stock up 25-33% in one session. The trend is your friend. Stock price recovered from the $1-range, now reaching 52/wk highs (at least attempting to) - soon to break through it. Plus, shorts are waving the white flag and walking away at a rate of 3-4% every week.
Both trends are your friends.
Sentiment: Strong Buy
Short interest is precisely 40% before the recent carnage from 3/15 through today's close.
It's probably 50-60% of float as I write this.
Are you slow or something? NASD data was released after-hours.
Do your research before you comment you fool.
Short interest jumped bro:
4/15/2015 4,826,704 1,562,953 3.088195
3/31/2015 2,914,567 1,520,462 1.916896
PCYC had a decent short interest too, right up to the time Abbvie ponied up $20+ billion for them.
Sometimes shorts ride it until the end both ways, buyout or to zero.
The MM's, hedge funds and manipulators played the game with GERN for about a year as well.
GERN has an outstanding float of 157/m and at peak, nearly 30/million were short. Needless to say, with some good news, partnership, the tide seems to be turning. While it's been a couple months, the short interest seems to be receding by about 1 to 1.5m every two weeks.
All shorts in the past 56/weeks are clearly on the wrong side of the trade with GERN. Only option will be cover or continue watching new 52/wk highs in the weeks and months ahead.
Granted it wasn't 40% of the float like CLDN, but it was about 20% at peak, now down to 15% of float.
Tides can change quickly or in GERN's case, slowly....but they do change, nonetheless.
Take a look at BLUE/ONCE/KITE/ADUR/QURE and lesser extent, CLDN, they all have pretty much major partnerships. All it takes is one partner to walk in and she's up 50-100% in a day with or without trial results.
CLDN is a lotto ticket.